
|Articles|October 6, 2017
Ophthalmology Times Bausch & Lomb Partner Perspective
Advertisement
Partner Perspectives
What is this?
×
Partner Perspectives allows marketers to connect directly with the Ophthalmology Times audience by enabling them to share their content. This content does not necessarily reflect the views of Ophthalmology Times editorial staff or UBM.
Learn more
Become a partner
PROLENSA® (bromfenac ophthalmic solution) 0.07%
Please see Indication and Important Safety Information for PROLENSA® on video.
Contact us: In order to provide more personalized service, we ask that you report any concerns with Bausch + Lomb Products via phone at 800-553-5340.
Product Concerns: 800-553-5340
Order Inquiries for professionals: 800-828-9030
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
2
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
3
Recognizing biomarkers of Alzheimer Disease using OCTA
4
Midyear cataract check-in: What 2026 has brought to the OR and beyond
5





















